HC Wainwright Cuts Outlook Therapeutics (NASDAQ:OTLK) Price Target to $3.00

Outlook Therapeutics (NASDAQ:OTLK) had its price target lowered by HC Wainwright from $30.00 to $3.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS, FY2028 earnings at $2.37 EPS and FY2029 earnings at $3.24 EPS.

Several other equities research analysts also recently commented on OTLK. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Guggenheim restated a “buy” rating and issued a $12.00 target price on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Outlook Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Outlook Therapeutics Stock Down 3.2 %

Shares of Outlook Therapeutics stock opened at $1.64 on Tuesday. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm has a market capitalization of $52.51 million, a PE ratio of -0.22 and a beta of 0.58. The stock’s fifty day moving average is $1.89 and its 200-day moving average is $4.33.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). Analysts expect that Outlook Therapeutics will post -2.25 EPS for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its stake in shares of Outlook Therapeutics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock worth $32,000 after acquiring an additional 17,119 shares during the last quarter. Commonwealth Equity Services LLC purchased a new position in Outlook Therapeutics in the fourth quarter valued at about $48,000. Jane Street Group LLC increased its position in Outlook Therapeutics by 133.9% in the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company’s stock worth $50,000 after purchasing an additional 15,008 shares during the last quarter. Christensen King & Associates Investment Services Inc. purchased a new stake in shares of Outlook Therapeutics during the 3rd quarter worth about $55,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Outlook Therapeutics by 44.8% during the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company’s stock valued at $56,000 after buying an additional 9,211 shares during the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.